ArticleBlood2019
Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03930394 (Vascular Cardiotoxicity of Ponatinib), which is not on this map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vascular Cardiotoxicity of Ponatinib
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Evaluating the use of rodents as in vitro, in vivo and ex vivo experimental models for the assessment of tyrosine kinase inhibitor-induced cardiotoxicity: a systematic review.Archives of toxicology · 2025Pooled it
- Mouse models to study von Willebrand factor in thrombosis: a scoping review.Research and practice in thrombosis and haemostasis · 2026Article
- A design approach for bitopic kinase inhibitors.Nature · 2026Article
- Mouse models to study von Willebrand factor in inflammation: a scoping review.Intensive care medicine experimental · 2026Review
- Ponatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling.Physiological reports · 2026Article
- Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis.Blood vessels, thrombosis & hemostasis · 2026Article
- Cardiovascular Disease in Patients With Chronic Myeloid Leukemia: JACC: CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
- Article
- Multifaceted roles of neutrophils in cardiac disease.Journal of leukocyte biology · 2025Review
- KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3Molecular cancer · 2025Article
- Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases.BMC neurology · 2025Article
- Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet function.The Journal of pharmacology and experimental therapeutics · 2025Article
- Immuno-inflammatory mechanisms in cardio-oncology: new hopes for immunotargeted therapies.Frontiers in oncology · 2025Review
- The Basic Principles of Pathophysiology of Venous Thrombosis.International journal of molecular sciences · 2024Review
- Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Ponatinib Induces a Procoagulant Phenotype in Human Coronary Endothelial Cells via Inducing Apoptosis.Pharmaceutics · 2024Article
- Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management.Journal of clinical medicine · 2024Review
- Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity.Circulation research · 2024Article
- Cancer and arterial thrombosis: therapeutic options.Research and practice in thrombosis and haemostasis · 2024Article
- AtypicalACS medicinal chemistry letters · 2023Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 6 institutions in 1 country.
Funding
Abstract
The third-generation tyrosine kinase inhibitor (TKI) ponatinib has been associated with high rates of acute ischemic events. The pathophysiology responsible for these events is unknown. We hypothesized that ponatinib produces an endothelial angiopathy involving excessive endothelial-associated von Willebrand factor (VWF) and secondary platelet adhesion. In wild-type mice and ApoE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.